KOL webinar: The eyonis® Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying

We invite you to watch this KOL webinar featuring two globally recognized U.S. pulmonology experts to get their views on the data from REALITY and how eyonis® LCS may impact lung cancer diagnostics and treatment practices in the real world. Panelists include Prof. Anil Vachani, from the Hospital of the University of Pennsylvania, and Prof. Javier Zulueta, from the Icahn School of Medicine at Mt Sinai. Fredrik Brag, CEO of Median Technologies, also participates and summarizes the final REALITY results, which are going to be submitted in H1 2025 to regulators for U.S. and EU marketing authorizations for eyonis® LCS.

Watch the video here

Early diagnosis saves lives

We are helping conquer cancer and fibrotic diseases by extracting invaluable clinical insights from patients’ medical images.

We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs. We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients.

About Us

We provide invaluable clinical insights where others see only images

We are a game changer in the medical space. Deploying our clinical expertise, proprietary technologies, and data science experience, we generate unprecedented insights from medical images for both drug development and patient care. We bring answers to your concerns and help therapeutic decisions.

Going beyond images

Our imaging solutions make an impact throughout the entire patient journey, from drug development to patient care.

Imaging Services for Oncology Clinical Trials

With iCRO we offer best-in-class end-to-end image management in oncology trials. We provide our global biopharma customers with key data on patients’ response to candidate drugs from phase I through phase III studies. Imaging Lab, our enriched iCRO offering, drives drug development success with transformative AI-powered insights.

Learn More

End-to-end CADe/CADx software as medical devices

With eyonis® we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis® is currently under development.

Learn More

The latest from Median

Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS

Median Technologies reports 2025 Q1 key financial indicators and provides an update on Q1 key operational achievements.

RELIVE pivotal study final results show that Median’s eyonis™ LCS SaMD met all key endpoints, demonstrating statistically significant performance, superior to state of the art, as well as device safety and efficacy. The results support the intended use for which eyonis™ LCS was developed, which was shared with the EU Notified Body and discussed with the FDA during the Q-submission phase.

Median will be exhibiting at the ESMO Congress on October 17 – 21 in Berlin. Happy to see you there at Messe Berlin!

Median will be exhibiting at the 2025 ASCO Annual Meeting, which will take place from May 30 to June 3 in Chicago, IL. Meet us at McCormick Place South, Hall A, Booth #11046 to learn more about our breakthrough imaging solutions and services for oncology clinical trials.

eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions

Median Technologies releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025.

Median will be exhibiting at the American Thoracic Society (ATS) International Conference in San Francisco, from May 18-21, 2025. Meet us at Moscone Center, Hall A B C, Booth #1662 to explore our eyonis™ LCS: our cutting-edge AI/ML-based CADe/CADx SaMD for Lung cancer screening.

Invest in us

Our innovative technology and leading expertise is opening up new possibilities for biopharmaceutical companies and healthcare professionals around the world.

By successfully helping improve the lives of millions, we are delivering value for our investors and partners.

Our company is listed on Euronext Growth and our shareholding structure reflects our global reach, with major shareholders from Europe, USA, and Asia.

Investors

Work with us

Being part of Median doesn’t just mean working for a company at the cutting edge of medical imaging. You become part of a team striving to improve outcomes for people suffering from life-threatening diseases. Join us!

Careers